别名 claudin 18、Claudin-18、CLDN18 + [2] |
简介 Involved in alveolar fluid homeostasis via regulation of alveolar epithelial tight junction composition and therefore ion transport and solute permeability, potentially via downstream regulation of the actin cytoskeleton organization and beta-2-adrenergic signaling (By similarity). Required for lung alveolarization and maintenance of the paracellular alveolar epithelial barrier (By similarity). Acts to maintain epithelial progenitor cell proliferation and organ size, via regulation of YAP1 localization away from the nucleus and thereby restriction of YAP1 target gene transcription (By similarity). Acts as a negative regulator of RANKL-induced osteoclast differentiation, potentially via relocation of TJP2/ZO-2 away from the nucleus, subsequently involved in bone resorption in response to calcium deficiency (By similarity). Mediates the osteoprotective effects of estrogen, potentially via acting downstream of estrogen signaling independently of RANKL signaling pathways (By similarity).
Involved in the maintenance of homeostasis of the alveolar microenvironment via regulation of pH and subsequent T-cell activation in the alveolar space, is therefore indirectly involved in limiting C. neoformans infection.
Required for the formation of the gastric paracellular barrier via its role in tight junction formation, thereby involved in the response to gastric acidification. |
靶点 |
作用机制 CLDN18.2抑制剂 [+2] |
在研适应症 |
最高研发阶段批准上市 |
首次获批国家/地区 日本 |
首次获批日期2024-03-26 |
靶点 |
作用机制 CLDN18.2抑制剂 |
在研机构 明济生物制药(北京)有限公司初创企业 |
原研机构 明济生物制药(北京)有限公司初创企业 |
在研适应症 |
非在研适应症- |
最高研发阶段临床3期 |
首次获批国家/地区- |
首次获批日期1800-01-20 |
作用机制 CLDN18.2抑制剂 [+1] |
在研机构 |
非在研适应症- |
最高研发阶段临床3期 |
首次获批国家/地区- |
首次获批日期1800-01-20 |
开始日期2024-11-10 |
申办/合作机构 |
开始日期2024-09-01 |
申办/合作机构 复旦大学 [+1] |
开始日期2024-08-06 |
申办/合作机构 |